On Friday, Aeropostale Inc (NYSE:ARO)’s shares declined -2.79% to $2.79.
Aeropostale Inc (ARO) will be holding its quarterly earnings conference call for all interested parties on Thursday, May 21, 2015 at 4:15 PM (ET).
The live conference call can be accessed via audio webcast at the Investor Relations section of the Company’s website, located at www.aeropostale.com or by dialing 877-407-9039 about 10 minutes preceding to the planned time with the passcode “Aeropostale.”
éropostale, Inc. operates as a specialty retailer of casual apparel and accessories for 14 to 17 year-old young women and men. It operates through two segments, Retail Stores and E-Commerce, and International Licensing.
Pandora Media Inc (NYSE:P)’s shares dropped -2.66% to $18.31.
Pandora Media Inc (P) declared that the company’s Chief Financial Officer, Mike Herring, will present at the J.P. Morgan Global Technology, Media and Telecom Conference in Boston, MA.
Mr. Herring will engage in a fireside chat on Tuesday, May 19, 2015 at 6:20 a.m. PT / 9:20 a.m. ET.
Pandora Media, Inc. provides Internet radio services in the United States. The company allows listeners to create up to 100 personalized stations to access free music and comedy catalogs, in addition to offers Pandora One, a paid subscription service to listeners.
At the end of Friday’s trade, Energy XXI Ltd (NASDAQ:EXXI)‘s shares dipped -1.40% to $3.57.
Energy XXI Ltd (EXXI) declared Chairman, President and Chief Executive Officer John Schiller will present at the UBS Global Oil and Gas Conference in Austin, Texas on Tuesday, May 19, 2015 at 10:35 a.m. Central Time.
Energy XXI (Bermuda) Limited is engaged in the acquisition, exploration, development, production, and operation of oil and natural gas properties onshore in Louisiana and Texas, and on the Gulf of Mexico.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), ended its Friday’s trading session with -2.38% loss, and closed at $0.431.
AEterna Zentaris Inc. (USA) (AEZS) stated financial and operating results for the first quarter ended March 31, 2015.
Research and development (“R&D”) costs, were $4.5 million for the three-month period ended March 31, 2015, contrast to $5.8 million for the same period in 2014. This decrease is attributable to lower comparative employee compensation and benefits costs, facilities rent and maintenance in addition to other costs. A substantial portion of this decrease is due to the realization of cost savings in connection with the Company’s global resource optimization program in addition to the lower comparative exchange rate of the EUR against the US dollar. This decrease was partly compensated by higher third-party costs, mostly related to the Company’s ZoptEC Phase 3 clinical trial in endometrial cancer.
Net loss for the three-month period ended March 31, 2015 was $9.7 million, or $0.13 per basic and diluted share, contrast to $4.4 million, or $0.08 per basic and diluted share, for the same period in 2014. This enhance in net loss is due largely to higher comparative SG&A expenses and to higher comparative net finance costs, partially offset by lower comparative R&D costs.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
